22.9 C
New York
Saturday, September 25, 2021

Why OpGen, Inc. (OPGN) rallied in Pre-Market?

OpGen, Inc. (OPGN) announced the publication of the final study results of the Unyvero HPN panel on Monday after which the OPGN stock price saw a jump of 36.73% at the time of closing. The OpGen stock remained green in the pre-market and reached $3.95 per share with a 47.39% gain as of this writing. Let’s understand more of it.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


What’s happening?

OpGen Inc is a medicine company that develops and provides molecular products to cope with infectious diseases. The company’s recent publication demonstrated its Unyvero Hospitalized Pneumonia (HPN) takes just five hours to detect bacterial pathogens from the lower respiratory tract of hospitalized  COVID-19 patients with pneumonia. The Unyvero HPN is a reliable panel as it provides accurate results with a high negative predictive value of 99.8% for the detection of pathogens.

There are many other advantages of the HPN panel as it enables detection of additional important pathogens such as Staphylococcus aureus, Pseudomonas aeruginosa, Serratia marcescens, Haemophilus influenzae, Stenotrophomonas maltophilia, and several others, thus resulting in higher diagnostic yield as compared Standard of Care (SoC) alone.

The company’s management said that they are happy about the strong performance of the HPN panel as it is necessary to detect bacterial pneumonia earlier in the hospital journey of COVID-19 patients.

About a week ago, the OpGen announced the regulatory approval of the Curetis Unyvero System as an in vitro diagnostics (IVD) instrument system in China by National Medical Products Administration, NMPA.

In the mid of February, OpGen subsidiary, Ares Genetics released its publications that demonstrated the best practice techniques AI-powered Prediction of Antibiotic Susceptibility Testing(AST) that resulted from whole-genome sequencing data.

 Conclusion

Things are going well for OPGN stock after the release of its publication related to the HPN panel. Accurate results of HPN panel with less diagnostic time of bacterial co-infections in COVID-19 patients is a big success for the company as it will greatly contribute to the treatment of COVID-19 patients in the future. The rising OPGN stock price is now captivating the attention of investors and hence it can be a good bet for investors in the future.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Related Articles

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Latest Articles

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam

Get The Best Stocks To Trade Every Day!

Join now to get the Newsheater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.